These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Treanor JJ; El Sahly H; King J; Graham I; Izikson R; Kohberger R; Patriarca P; Cox M Vaccine; 2011 Oct; 29(44):7733-9. PubMed ID: 21835220 [TBL] [Abstract][Full Text] [Related]
23. Dose-response relationship after immunization of volunteers with a new, surface-antigen-adsorbed influenza virus vaccine. Potter CW; Jennings R; Phair JP; Clarke A; Stuart-Harris CH J Infect Dis; 1977 Mar; 135(3):423-31. PubMed ID: 850080 [TBL] [Abstract][Full Text] [Related]
24. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948 [TBL] [Abstract][Full Text] [Related]
26. [Clinical control, study of viral shedding and evaluation of circulating and local antibody response after administration of live and attenuated "Alice" strain influenza vaccine]. Bergamini F; Profeta ML; Ferroni P; Zanetti AR Boll Ist Sieroter Milan; 1976 Mar; 55(71):1-12. PubMed ID: 1021151 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of live attenuated influenza A/Scotland/74 (H3N2) virus vaccine against challenge with influenza A/Victoria/3/75 (H3N2) virus. Betts RF; Douglas RG; Roth FK; little JW J Infect Dis; 1977 Dec; 136(6):746-53. PubMed ID: 925382 [TBL] [Abstract][Full Text] [Related]
28. An attenuated influenza virus vaccine: protection against homologous and heterologous strains of virus. Lee JD; Khakoo RA; Street CK; Waldman RH J Infect Dis; 1977 May; 135(5):824-7. PubMed ID: 870566 [TBL] [Abstract][Full Text] [Related]
29. Comparative trials of live attenuated and detergent split influenza virus vaccines. Mackenzie JS; Mackenzie I; Lloyd J; Dent V J Hyg (Lond); 1975 Dec; 75(3):425-43. PubMed ID: 1059709 [TBL] [Abstract][Full Text] [Related]
30. Response of ferrets to infection with a live attenuated influenza virus and to subsequent heterologous challenge. Delem A Dev Biol Stand; 1976; 33():226-33. PubMed ID: 955269 [TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042 [TBL] [Abstract][Full Text] [Related]
32. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. Monto AS; Petrie JG; Cross RT; Johnson E; Liu M; Zhong W; Levine M; Katz JM; Ohmit SE J Infect Dis; 2015 Oct; 212(8):1191-9. PubMed ID: 25858957 [TBL] [Abstract][Full Text] [Related]
33. A trial of live virus intra-nasal influenza vaccine. Dodge JS N Z Med J; 1978 Feb; 87(605):79-82. PubMed ID: 273801 [TBL] [Abstract][Full Text] [Related]
34. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study. Rudenko L; Kiseleva I; Stukova M; Erofeeva M; Naykhin A; Donina S; Larionova N; Pisareva M; Krivitskaya V; Flores J; Vaccine; 2015 Sep; 33(39):5110-7. PubMed ID: 26296497 [TBL] [Abstract][Full Text] [Related]
35. Serum antibody responses after intradermal vaccination against influenza. Belshe RB; Newman FK; Cannon J; Duane C; Treanor J; Van Hoecke C; Howe BJ; Dubin G N Engl J Med; 2004 Nov; 351(22):2286-94. PubMed ID: 15525713 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417 [TBL] [Abstract][Full Text] [Related]
37. Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. Potter CW; Jennings R; Nicholson K; Tyrrell DA; Dickinson KG J Hyg (Lond); 1977 Dec; 79(3):321-32. PubMed ID: 270523 [TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial. Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672 [TBL] [Abstract][Full Text] [Related]
39. Natural challenge of subjects vaccinated with WRL 105 strain live influenza vaccine in a residential community. Morris CA; Freestone DS; Stealey VM Dev Biol Stand; 1976; 33():197-201. PubMed ID: 782969 [TBL] [Abstract][Full Text] [Related]
40. Preliminary results of oral influenza vaccination with live attenuated viruses. DeBarbieri A; Crovari P; Cuneo-Crovari P; Badolati G; Giacometti G Dev Biol Stand; 1976; 33():213-9. PubMed ID: 782972 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]